(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.
Palvella Therapeutics's earnings in 2025 is -$17,434,000.On average, 3 Wall Street analysts forecast PVLA's earnings for 2025 to be -$111,876,644, with the lowest PVLA earnings forecast at -$173,324,890, and the highest PVLA earnings forecast at -$26,775,555. On average, 3 Wall Street analysts forecast PVLA's earnings for 2026 to be -$103,943,146, with the lowest PVLA earnings forecast at -$139,607,524, and the highest PVLA earnings forecast at -$33,717,366.
In 2027, PVLA is forecast to generate -$117,514,937 in earnings, with the lowest earnings forecast at -$152,058,709 and the highest earnings forecast at -$82,971,165.